Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease

Autor(es)

Lara, Leonardo da Silva ^[1] ; Andrade-Lima, Leonardo ^[2] ; Calvet, Claudia Magalhaes ^[1] ; Borsoi, Juliana ^[2] ; Alberto Duque, Thabata Lopes ^[3] ; Henriques-Pons, Andrea ^[4] ; Souza Pereira, Mirian Claudia ^[1] ; Pereira, Lygia Veiga ^[2]

Afiliação do(s) autor(es)

^[1] Fiocruz MS, Inst Oswaldo Cruz, Lab Ultraestrutura Celular, Av Brasil 4365, BR-21045900 Manguinho, RJ - Brazil

^[2] Univ Sao Paulo, Inst Biosci, Natl Lab Embryon Stem Cells LaNCE, BR-05508090 Sao Paulo, SP - Brazil

^[3] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Celular, Manguinho, RJ - Brazil

^[4] Fiocruz MS, Inst Oswaldo Cruz, Lab Inovacoes Terapias Ensino & Bioprod, Av Brasil 4365, BR-21045900 Manguinho, RJ - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Microbes and Infection; v. 20, n. 5, p. 312-316, MAY 2018.
• Citações Web of Science: 0

Resumo

Chagas disease, caused by Trypanosoma cruzi, is an important global public health problem which, despite partial efficacy of benznidazole (Bz) in acute phase, urgently needs an effective treatment. Cardiotoxicity is a major safety concern for conduction of more accurate preclinical drug screening platforms. Human induced pluripotent stem cells derived cardiomyocytes (hiPSC-CM) are a reliable model to study genetic and infectious cardiac alterations and may improve drug development. Herein, we introduce hiPSC-CM as a suitable model to study T. cruzi heart infection and to predict the safety and efficacy of anti-T. cruzi drugs. (C) 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved. (AU)

• Processo FAPESP: 13/08135-2 - CTC - Centro de Terapia Celular
• Beneficiário: Dimas Tadeu Covas
• Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs